USPH Quote, Financials, Valuation and Earnings

Encompass Health Corp. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of 11.82%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat Encompass Health Corp.'s return on equity of 24.34%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 30.04%. On the other hand Encompass Health Corp. has an analysts' consensus of $140.33 which suggests that it could grow by 30.52%. Given that Encompass Health Corp. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe Encompass Health Corp. is more attractive than U.S. Physical Therapy, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.320, which suggesting that the stock is 32.001% more volatile than S&P 500. In comparison Encompass Health Corp. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.418%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.22%. Encompass Health Corp. offers a yield of 0.65% to investors and pays a quarterly dividend of $0.19 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. Encompass Health Corp. pays out 14.35% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are smaller than Encompass Health Corp. quarterly revenues of $1.5B. U.S. Physical Therapy, Inc.'s net income of $19.7M is lower than Encompass Health Corp.'s net income of $174.7M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 34.08x while Encompass Health Corp.'s PE ratio is 20.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.62x versus 1.90x for Encompass Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD, Inc. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of -22162.75%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat Kindly MD, Inc.'s return on equity of -91.57%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 30.04%. On the other hand Kindly MD, Inc. has an analysts' consensus of $1.25 which suggests that it could grow by 226.97%. Given that Kindly MD, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe Kindly MD, Inc. is more attractive than U.S. Physical Therapy, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.320, which suggesting that the stock is 32.001% more volatile than S&P 500. In comparison Kindly MD, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.22%. Kindly MD, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. Kindly MD, Inc. pays out -- of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are larger than Kindly MD, Inc. quarterly revenues of $388.2K. U.S. Physical Therapy, Inc.'s net income of $19.7M is higher than Kindly MD, Inc.'s net income of -$86M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 34.08x while Kindly MD, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.62x versus 10.71x for Kindly MD, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SRx Health Solutions, Inc. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of -13.47%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat SRx Health Solutions, Inc.'s return on equity of --.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 30.04%. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that U.S. Physical Therapy, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe U.S. Physical Therapy, Inc. is more attractive than SRx Health Solutions, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.320, which suggesting that the stock is 32.001% more volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.069%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.22%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are larger than SRx Health Solutions, Inc. quarterly revenues of $7.2M. U.S. Physical Therapy, Inc.'s net income of $19.7M is higher than SRx Health Solutions, Inc.'s net income of -$964K. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 34.08x while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.62x versus 0.05x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute, Inc. has a net margin of 9.98% compared to U.S. Physical Therapy, Inc.'s net margin of -10.08%. U.S. Physical Therapy, Inc.'s return on equity of 8.6% beat The Oncology Institute, Inc.'s return on equity of -9486.64%.

U.S. Physical Therapy, Inc. has a consensus price target of $105.33, signalling upside risk potential of 30.04%. On the other hand The Oncology Institute, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 78.57%. Given that The Oncology Institute, Inc. has higher upside potential than U.S. Physical Therapy, Inc., analysts believe The Oncology Institute, Inc. is more attractive than U.S. Physical Therapy, Inc..

U.S. Physical Therapy, Inc. has a beta of 1.320, which suggesting that the stock is 32.001% more volatile than S&P 500. In comparison The Oncology Institute, Inc. has a beta of 0.162, suggesting its less volatile than the S&P 500 by 83.817%.

U.S. Physical Therapy, Inc. has a quarterly dividend of $0.45 per share corresponding to a yield of 2.22%. The Oncology Institute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. U.S. Physical Therapy, Inc. pays 95.62% of its earnings as a dividend. The Oncology Institute, Inc. pays out -- of its earnings as a dividend. U.S. Physical Therapy, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

U.S. Physical Therapy, Inc. quarterly revenues are $197.1M, which are larger than The Oncology Institute, Inc. quarterly revenues of $136.6M. U.S. Physical Therapy, Inc.'s net income of $19.7M is higher than The Oncology Institute, Inc.'s net income of -$13.8M. Notably, U.S. Physical Therapy, Inc.'s price-to-earnings ratio is 34.08x while The Oncology Institute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for U.S. Physical Therapy, Inc. is 1.62x versus 0.68x for The Oncology Institute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.